PremiumThe FlyVaxart CSO Sean Tucker provides video update for shareholders Vaxart Discusses Reverse Stock Split and Capital Raise Vaxart Begins Phase 2b Trial for Oral COVID-19 Vaccine PremiumThe FlyVaxart approves resolutions to narrow reverse split range, reduce shares Vaxart’s Earnings Call: Growth Amid Challenges Vaxart Receives BARDA Approval for Phase 2b Trial PremiumThe FlyVaxart CFO Phillip Lee resigns, Jeroen Grasman succeeds Options Volatility and Implied Earnings Moves Today, May 13, 2025 Vaxart Proposes Reverse Stock Split to Avoid Delisting